An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Harvoni

Chemical Nameledipasvir/sofosbuvir
Dosage FormTablet (oral; ledipasvir/sofosbuvir (90mg/400mg, 45mg/ 200mg)); Pellet (oral; ledipasvir/sofosbuvir (45mg/200mg, 33.75mg/150mg))
Drug ClassInhibitors
SystemBlood
CompanyGilead Sciences Inc.
Approval Year2014

Indication

  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 or 4 infection who are liver transplant recipients without.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Harvoni (ledipasvir and sofosbuvir) Prescribing Information2019Gilead Sciences, Inc., Foster City, CA
Document TitleYearSource
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.2019Journal of Hepatology
Systematic review with meta-analysis: Efficacy and safety of direct-acting antivirals for chronic hepatitis C genotypes 5 and 6.2019Biomed Research International
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.2018Aliment Pharmacology and Therapeutics
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis.2017International Journal of Infectious Diseases
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.2016Journal of Gastroenterology and Hepatology